1 / 47

Administrative Principles of Vaccination Prof. Dr. AHMET ARVAS

Administrative Principles of Vaccination Prof. Dr. AHMET ARVAS I.U. Cerrahpasa Medical Faculty , Department of Pediatrics. Vaccine preventable diseases. infant mortality in world -2010. Lancet 2012;380:2095-125. child mortality -2010 (1-4 y). Lancet 2012;380:2095-125.

avak
Download Presentation

Administrative Principles of Vaccination Prof. Dr. AHMET ARVAS

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. AdministrativePrinciples of Vaccination Prof. Dr. AHMET ARVAS I.U. CerrahpasaMedicalFaculty, Department of Pediatrics

  2. Vaccinepreventablediseases

  3. infantmortality in world-2010 Lancet 2012;380:2095-125

  4. childmortality-2010 (1-4 y) Lancet 2012;380:2095-125

  5. Vaccinepreventabledeaths in world-2008 Measles118.000 Hibinf.199.000 Pertussis195.000 Tetanus 2.000 N. Tetanus59.000 Yellowfever30.000 Diphteria4.000 Rotavirusinf.453.000 Pneumococcaldis.476.000 Hepatitis B inf. 10.000 1.5 million of deathsamongchildrenunder 5 yearsaredueto diseasesthatcouldhavebeenpreventedbyroutinevaccination

  6. Measles: 2011:111; 2012:101 cases

  7. Activevaccination • Protectionproducedbyvaccine • Usuallypermanent • Immunityandimmunologicmemorysimilartonaturalinfection but without risk of disease

  8. Classification of vaccines • Liveattenuated • bacterial • viral • Inactivated • whole: viruses, bacteria • fractional: protein based (toxoid, subunit) • polysaccharide-based (pure, conjugate)

  9. Live Attenuated Vaccines • Attenuated (weakened) form of the "wild" virus or bacterium • Must replicate to be effective • Immune response similar to natural infection • Usually produce immunity with one dose (exceptthoseadministratedorally) *except those administered orally

  10. Inactivated Vaccines • Cannot replicate • Generally not as effective as live vaccines • Less interference from circulating antibody than live vaccines • Generally require 3-5 doses • Immune response mostly humoral • Antibody titer may diminish with time

  11. General Rules • Inactivated vaccines are generally not affected by circulating antibody to the antigen • Live attenuated vaccines may be affected by circulating antibody to the antigen

  12. Polysaccharide Vaccines Purepolysaccharide • pneumococcal • meningococcal • SalmonellaTyphi (Vi) • Haemophilusinfluenzae type b • Pneumococcal (PCV-7, PCV-10, PCV13) • Meningococcal (MenC, MCV4) Conjugate polysaccharide

  13. 2012 Immunization Schedule-Turkey birth 1 month 2 months 4 months 6 months Firstschoolgrade (6 yrs) Eighthschoolgrade (13-14 yrs) m m P v B PCV B MMR B OPV DaPT/IPV + HepA II Varicella ı

  14. Immunizationcoverage rate in Turkey (%) Source: TurhishHealthMinistryPublicHealthInstitute

  15. Immunizationschedule (unvaccinatedchildren: > 1 year)

  16. All vaccines can be administered at the same visit as all other vaccines

  17. Spacing of Vaccine Combinations Not Given Simultaneously Minimum Interval 4 weeks None Combination twolive injected or intranasal influenza vaccine allother

  18. Increasing the interval between doses of a multidose vaccine does not diminish the effectiveness of the vaccine. It is not necessary to restart the series or add doses because of an extended interval between doses • Decreasing the interval between doses of a multidose vaccine may interfere with antibody response and protection • Vaccine doses should not be administered at intervals less than the minimum intervals or earlier than the minimum age *after the series has been completed

  19. Time limitsforusingvaccinesafterreconstitution MMR≤ 8 hrs BCG ≤ 4-8 hrsprotectfromligth Varicella ≤ 30 min

  20. Types of administrationerrors • wrongvaccineorwrongdiluent • wrongedosage • expiredvaccine • wrongroute/site/needle size • wrong time • wrongpatient

  21. Correctroute, site, needle size

  22. Vaccine Adverse Reactions • Local • pain, swelling, redness at site of injection • common with inactivated vaccines • usually mild and self-limited

  23. Vaccine Adverse Reactions • Systemic • fever, malaise, headache • nonspecific • may be unrelated to vaccine

  24. Vaccine Adverse Reactions • Allergic • due to vaccine or vaccine component • rare • risk minimized by screening

  25. Contraindication • A condition in a recipient that greatly increases the chance of a serious adverse reaction

  26. Precaution • A condition in a recipient that might increase the chance or severity of an adverse reaction, or • Might compromise the ability of the vaccine to produce immunity

  27. Contraindications Permanent contraindications to vaccination: • severe allergic reaction to a vaccine component or following a prior dose (anaphylacticreaction: allvaccines) • Encephalopathy/encephalitisnot due to another identifiable cause occurring within 7 days of pertussisvaccination • Severe combinedimmunodeficiency (livevaccines)

  28. Immunosuppression • Disease • congenital immunodeficiency • leukemia or lymphoma • generalized malignancy • Chemotherapy • alkylating agents • antimetabolites • radiation

  29. Immunosuppression • Corticosteroids • 20 mg or more per dayof prednisone* • 2 mg/kg or more per day of prednisone* • NOT aerosols, alternate day, short courses, topical *for 14 days or longer

  30. Vaccination of householdcontactsof immunosuppressedpersons • Healthy household contacts of immunosuppressed persons should receive MMR and varicella vaccines and annual influenza vaccination

  31. Invalid contraindicationsto vaccination • Mild illness • Antimicrobial therapy • Disease exposure or convalescence • Pregnant or immunosuppressed person in the household • Breastfeeding • Preterm birth • Allergy to products not present in vaccine or allergy that is not anaphylactic • Family history of adverse events • Tuberculin skin testing • Multiple vaccines

  32. Vaccination duringacute illness • No evidence that acute illness reduces vaccine efficacy or increases vaccine adverse reactions • Vaccines should be delayed until the illness has improved • Mild illness, such as otitis media or an upper respiratory infection, is NOT a contraindication to vaccination

  33. Missed opportunity A healthcare encounter in which a person is eligible to receive vaccination but is not vaccinated completely

  34. Reasons for missedopportunities • Lack of simultaneous administration • Unaware child needs additional vaccines • Invalid contraindications • Inappropriate clinic policies

  35. Vaccine Adverse Event Reporting System (VAERS) National reporting system

  36. Vaccine Adverse Event Reporting System (VAERS) • Detects • new or rare events • increases in rates of known side effects • patient risk factors • Additional studies required to confirm VAERS signals • Not all reports of adverse events are causally related to vaccine

  37. AdverseEventClassification • Vaccine-induced: Due to the intrinsic characteristic of the vaccine preparation and the individual response of the vaccinee. These events would not have occurred without vaccination (e.g., vaccine-associated paralytic poliomyelitis after oral polio vaccine). • Vaccine-potentiated: The event would have occurred anyway, but was precipitated by the vaccination (e.g., first febrile seizure in a predisposed child). • Programmatic error: Due to technical errors in vaccine storage, preparation, handling, or administration. • Coincidental: The reported event was not caused by vaccination but happened by chance occurrence or due to underlying illness.

  38. Vaccine-associatedparalyticpolio (VAPP): overallincidence of oncecase of VAPP: per 2.4 milliondoses of OPV Rotavirusvaccine/ increased risk of intussusception: no evidencefor a causallink (coins.) MMR-V: additional 4.3 febrileseizuresper 10.000 MMR-V dosescomparedto MMR and V administeredseparately MCV4/ Guillain-BarreSyndrome: no evidencefor a causal link (coincidental) Hep B V/ Guillain-BarreSyndrome, transversemyelitis: no evidencefor a causal link MMR/ autism, inflammatoryboweldiseases: no evidencefor a causal link (coinc.) Thimerosal (mercurycontainingpreservative)-containingvaccines/ autism, inflammatory boweldiseases, ADHD : no evidencefor a causal link (coincidental) Vaccines/ ITP: vaccinepotentiated

More Related